<DOC>
	<DOCNO>NCT00654498</DOCNO>
	<brief_summary>To determine efficacy safety Pramipexole 0.125mg 0.75mg daily 6 week compare placebo treatment idiopathic Restless Legs Syndrome ( RLS )</brief_summary>
	<brief_title>Pramipexole Out-patients With Idiopathic Restless Legs Syndrome ( IRLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Written inform consent consistent International Conference Harmonisation ( ICH ) / Good Clinical Practice ( GCP ) local legislation give prior study procedure . 2 . Ability willingness comply study treatment regimen attend study assessment . 3 . Male female outpatient age 1880 year . 4 . Diagnosis idiopathic Restless Legs Syndrome ( IRLS ) accord clinical Restless Legs Syndrome ( RLS ) criteria International Restless Legs Syndrome Study Group ( IRLSSG ) All four criterion must present fulfil diagnosis RLS : An urge move leg , usually accompany cause uncomfortable unpleasant sensation leg . ( Sometimes urge move present without uncomfortable sensation sometimes arm body part involve addition leg ) . The urge move unpleasant sensation begin worsen period rest inactivity lie sit . The urge move unpleasant sensation partially totally relieved movement , walk stretch , least long activity continue . The urge move unpleasant sensation worse even night day occur even night . ( When symptom severe , worsen night may noticeable must previously present ) . 5 . Restless Legs Syndrome ( RLS ) rating scale severity total score &gt; 15 . 6 . Restless Legs Syndrome ( RLS ) symptoms present least 2 3 day per week last 3 month . 1 . Women childbearing potential ( i.e . premenopausal woman , postmenopausal woman le 2 year last menses ) use clinical trial adequate method contraception : hormonal therapy ( combined oral contraceptive , injectables , subcutaneous implant ) , hormonal intrauterine device , sexual abstinence , surgical sterilization patient and/or partner , hysterectomy , bilateral ovariectomy partner vasectomy 2 . Any woman childbearing potential negative pregnancy test screen 3 . Patients breastfeed 4 . Concomitant previous pharmacologically therapy RLS follow : Any intake levodopa within 5 day prior baseline visit ( V2 ) Any intake dopamine agonist within 14 day prior baseline visit ( V2 ) 5 . Current ( less 14 day treatment trial medication concomitant ) treatment medication dietary supplement , could significantly influence RLS symptom , e.g . dopaminergic ( levodopa dopamine agonist ) antidopaminergic drug , nonselective Monoamine Oxidase ( MAO ) inhibitor , sympathomimetics , neuroleptic , antidepressant , hypnotic , benzodiazepine , antiepileptic , opioids , clonidine , magnesium , ferrous salt , Folic acid , vitamin B12 , antihistaminics , lithium , metoclopramide Withdrawal symptom cause stop drug 6 . Confirmed diagnose diabetic nephropathy clinically significant renal disease 7 . Creatinine high upper limit normal ( ULN ) screen 8 . Clinical significant hepatic disease Alanine aminotransferase ( ALT ) &gt; 2 time upper limit normal range screen 9 . Clinical laboratory sign microcytic anaemia , ferritin serum low bound reference range 10 . Any following lab result screen : Basal Thyroid Stimulating Hormone ( TSH ) , T3 T4 clinically significantly ( investigator discretion ) normal range screening ( cause substitution therapy accord investigator opinion ) Patients clinically significant abnormality laboratory parameter screen investigator discretion 11 . Other clinically significant metabolicendocrine , haematological , gastrointestinal disease pulmonary disease ( severe COPD ) . Poorly control cardiovascular disease ( include hypotension severe coronary artery disease ) 12 . History clinical sign peripheral neuropathy ( PNP ) origin physical , neurological examination , myelopathy multiple sclerosis neurological disease , potential secondarily cause RLS symptom 13 . Presence sleep disorder , , Rapid Eye Movement ( REM ) sleep behaviour disorder , narcolepsy sleep apnoea syndrome 14 . History Schizophrenia psychotic disorder , history mental disorder due general medical condition present axis I psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSM IV ) require medical therapy 15 . History alcohol abuse drug addiction within last 2 year screen 16 . Participation drug study within two month prior start study 17 . History clinical sign form epilepsy seizure apart fever related seizure early childhood 18 . History clinical sign malign neoplasm 19 . Patients shiftworkschedule , otherwise unable follow regular sleepwake cycle enable use study medication time indicate 20 . Any condition opinion investigator would interfere evaluation result constitute health hazard subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>